Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing DM199, a recombinant form of human tissue kallikrein-1, to treat severe ischemic diseases like acute ischemic stroke and preeclampsia. Its therapies aim to improve blood flow, reduce inflammation, and promote vascular health. The company focuses on clinical trials, regulatory approval, and strategic partnerships to address unmet medical needs in neurology and obstetrics markets worldwide.
This description was generated via AI from an annual report. Updated about 1 year ago.